APA (7th ed.) Citation

X, S., T, K., J, X., Y, X., AN, S., M, M., . . . KN, W. (2026). CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy. Journal of bone oncology, 58, 100765. https://doi.org/10.1016/j.jbo.2026.100765

Chicago Style (17th ed.) Citation

X, Su, et al. "CDK4/6 Inhibitor Ribociclib and Doxorubicin Combination Treatment Inhibits Breast Cancer Bone Metastasis and Enhances T-cell Targeted Therapy." Journal of Bone Oncology 58 (2026): 100765. https://doi.org/10.1016/j.jbo.2026.100765.

MLA (9th ed.) Citation

X, Su, et al. "CDK4/6 Inhibitor Ribociclib and Doxorubicin Combination Treatment Inhibits Breast Cancer Bone Metastasis and Enhances T-cell Targeted Therapy." Journal of Bone Oncology, vol. 58, 2026, p. 100765, https://doi.org/10.1016/j.jbo.2026.100765.